Palbo 125 mg (Palbociclib) Capsule


Palbo 125 mg (Palbociclib) Capsule


Palbo 125 mg, crafted with precision by Drug International Ltd. and distributed by the unwavering efforts of Orio Pharma, stands as a beacon of progress in the realm of breast cancer treatment. With Palbociclib as its active ingredient, this medication represents a pivotal advancement in targeted therapy, offering new avenues of hope and efficacy for patients confronting the challenges of breast cancer.

Description and Usage: Palbo 125 mg (Palbociclib)

Palbo 125 mg is a targeted therapy meticulously developed for the treatment of advanced breast cancer. The active ingredient, Palbociclib, is a cyclin-dependent kinase (CDK) 4/6 inhibitor. It is specifically indicated for use in combination with hormone therapy for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer.

How Palbo 125 mg Works: Palbociclib operates by inhibiting CDK 4 and 6, key proteins involved in cell cycle progression. By doing so, it restrains the uncontrolled growth of cancer cells, particularly those driven by the HR+/HER2- subtype. This targeted approach enhances the efficacy of hormone therapy, providing a synergistic effect against the progression of advanced breast cancer.

Dosage and Administration:

The recommended dosage of Palbo 125 mg is typically administered orally once daily for 21 consecutive days, followed by a 7-day break to comprise a complete treatment cycle of 28 days. Palbo 125 mg is commonly prescribed in combination with an aromatase inhibitor or fulvestrant. Dosage adjustments and individualized treatment plans are made based on patient response and tolerability.


In the pursuit of more effective breast cancer treatments, Palbo 125 mg emerges as a transformative option for patients facing advanced stages of the disease. Its targeted mechanism, combined with the convenience of an oral regimen, marks a significant leap forward in personalized medicine. This approach not only enhances treatment efficacy but also underscores a commitment to patient well-being throughout their therapeutic journey.


Benefits of Palbo 125 mg:

  • Enhanced Efficacy: Palbo 125 mg, in combination with hormone therapy, has been shown to significantly improve progression-free survival in women with HR+/HER2- advanced or metastatic breast cancer, offering a more robust defense against disease progression.
  • Reduced Side Effects: By specifically targeting CDK 4 and 6, Palbo 125 mg minimizes adverse effects on healthy cells, contributing to a more favorable side effect profile compared to traditional chemotherapy.
  • Extended Treatment Options: Palbo 125 mg opens new avenues for women with hormone receptor-positive breast cancer, providing an effective and well-tolerated option for those who may not be candidates for more aggressive treatments.

Manufacturer: Drug International Ltd.:

The formulation and production of Palbo 125 mg are the result of the expertise and dedication of Drug International Ltd. This pharmaceutical innovator is committed to advancing healthcare through cutting-edge research and development, utilizing state-of-the-art manufacturing processes to ensure the consistency, safety, and efficacy of its products.

Supplier: Orio Pharma:

In the crucial role of distribution, Orio Pharma ensures that the benefits of Palbo reach healthcare providers and patients globally. Committed to excellence, Orio Pharma upholds stringent standards in the distribution process, ensuring timely and reliable access to Palbo 125 mg for those in need.

In conclusion, the collaboration between Drug International Ltd.’s manufacturing excellence and Orio Pharma’s commitment to distribution is instrumental in the success story of Palbo 125 mg. Together, they contribute to the ongoing battle against advanced breast cancer, exemplifying the collaborative spirit that propels medical advancements and offers renewed hope to patients and their families.